Sialoadhesin factor-2 antibodies

Abstract

Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents

What is claimed is:  
     
         1 . An antibody that binds to human SAF-2.  
     
     
         2 . The antibody of  claim 1  wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.  
     
     
         3 . The antibody of  claim 2 , wherein the antibody is monoclonal antibody 2C4.  
     
     
         4 . An isolated polypeptide comprising an immunoglobulin complementarity determining region of the antibody of  claim 1 .  
     
     
         5 . An isolated polypeptide comprising an immunoglobulin complementarity determining region of the antibody of  claim 2 .  
     
     
         6 . An isolated polypeptide comprising an immunoglobulin complementarity determining region of the antibody of  claim 3 .  
     
     
         7 . An isolated polynucleotide encoding the polypeptide of  claim 4 .  
     
     
         8 . An isolated polynucleotide encoding the polypeptide of  claim 5 .  
     
     
         9 . An isolated polynucleotide encoding the polypeptide of  claim 6 .  
     
     
         10 . The polypeptide of  claim 6  wherein the immunoglobulin complementarity determining region that comprises the polypeptide is set forth in a member of the group consisting of SEQ ID NO:5, 6, 7, 8, 9 and 10.  
     
     
         11 . The polypeptide of  claim 10  wherein the immunoglobulin complementarity determining region comprises the polypeptides set forth in SEQ ID NOs:3, 4 and 5.  
     
     
         12 . The polypeptide of  claim 10  wherein the immunoglobulin complementarity determining region comprises the polypeptides set forth in SEQ ID NOs:6, 7 and 8.  
     
     
         13 . An isolated polynucleotide encoding the polypeptide of  claim 10 .  
     
     
         14 . An isolated polynucleotide encoding the polypeptide of  claim 11 .  
     
     
         15 . An isolated polynucleotide encoding thc polypeptide of  claim 12 .  
     
     
         16 . The antibody of  claim 1  wherein the immunoglobulin complementarity determining region of the antibody comprises the polypeptides set forth in SEQ ID NO:5, 6, 7, 8, 9 and 10.  
     
     
         17 . The antibody of  claim 16  comprising a heavy chain variable region polypeptide as set forth in SEQ ID NO:2 and a kappa light chain variable region polypeptide as set forth in SEQ ID NO:4.  
     
     
         18 . An isolated polynucleotide encoding a polypeptide comprising a member selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.  
     
     
         19 . A hybridoma cell line that produces a monoclonal antibody having the identifying characteristics the monoclonal antibody 2C4.  
     
     
         20 . A pharmaceutical composition comprising the antibody of  claim 1 .  
     
     
         21 . A pharmaceutical composition comprising the antibody of  claim 2 .  
     
     
         22 . A pharmaceutical composition comprising the monoclonal antibody of  claim 3 .  
     
     
         23 . A method for detecting the presence of a cell in a sample wherein the cell comprises an SAF-2 protein, the method comprising: 
 a) exposing the sample to an antibody that binds to SAF-2; and    b) detecting the antibody that is bound to SAF-2.    
     
     
         24 . The method of  claim 23  wherein the sample is treated before exposure to the antibody such that the SAF-2 protein is accessible to binding by the antibody.  
     
     
         25 . The method of  claim 23  wherein the cell is a member selected from the group consisting of an eosinophil, a basophil and a mast cell.  
     
     
         26 . The method of  claim 23  wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.  
     
     
         27 . The method of  claim 26  wherein the antibody is monoclonal antibody 2C4.  
     
     
         28 . A method for altering the function or viability of a cell expressing SAF-2 comprising contacting the cell with a therapeutic agent that binds to SAF-2.  
     
     
         29 . The method of  claim 28  wherein the cell is selected from the group consisting of eosinophils, basophils and mast cells.  
     
     
         30 . The method of  claim 28  wherein the therapeutic agent is an antibody.  
     
     
         31 . The method of  claim 28  wherein contact with the therapeutic agent induces apoptosis of the cell.  
     
     
         32 . A method for preventing or treating a disease or condition mediated by cells expressing SAF-2, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a therapeutic agent that binds to SAF-2.  
     
     
         33 . The method of  claim 32  wherein the disease is an allergic, asthmatic or cancerous disease or a hypereosinophilic syndrome.  
     
     
         34 . The method of  claim 33  wherein the disease is a member selected from the group consisting of asthma, allergic rhinitis, atopic dermatitis, chronic urticaria, nasal polyposis, Churg-Strauss Syndrome, allergic bronchopulmonary Aspergillosis or eosinophilic leukemia, eczema, systemic mastocytosis, lymphoma, eosinophilic leukemia and basophilic leukemia.  
     
     
         35 . The method of  claim 32  wherein the therapeutic agent is an antibody.  
     
     
         36 . The method of  claim 35  wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.  
     
     
         37 . The method of  claim 32  wherein the pharmaceutical composition further comprises a cytokine.  
     
     
         38 . The method of  claim 37  wherein the cytokine is a member selected from the group consisting of IL-5 and GM-CSF.  
     
     
         39 . A pharmaceutical composition comprising an effective amount of a therapeutic agent that binds to SAF-2.  
     
     
         40 . The pharmaceutical composition of  claim 39  wherein the therapeutic agent is an antibody.  
     
     
         41 . The pharmaceutical composition of  claim 40  wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.